To the full analysis
Lakefront Biotherapeutics stock: growth
LKFTLakefront Biotherapeutics reported $1.23B in revenue for fiscal 2025, up 303.5% on the prior year, up 47.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
47.6%
per year from 2021 to 2025, per share 41.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | |
|---|---|
| Revenue | 47.6% |
| Revenue per share | 41.7% |
| Earnings | no data |
| Earnings per share | no data |
| Free cash flow | no data |
| Free cash flow per share | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2021 | $259.72M | −$114.39M | $0 |
| 2022 | $267.33M | −$241.56M | $0 |
| 2023 | $265.64M | $234.58M | $0 |
| 2024 | $305.45M | $82.09M | $0 |
| 2025 | $1.23B | $355.57M | −$300.64M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 23 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.